Smo mutations can be divided in the following groups: (1) passenger mutations that do not contribute to cancer progression; (2) oncogenic mutations that stabilise the active form of Smo and release it from the inactive state conformational constraints; (3) resistance mutations that prevent effective drug binding. Here, SMO is linked to cancer.